UT Dallas Researchers Advance Non-Opioid Neuropathic Pain Medication

Breakthrough at UT Dallas: Pioneering Non-Opioid Solutions for Neuropathic Pain

In the ongoing battle against chronic pain, researchers at the University of Texas at Dallas (UT Dallas) are leading the charge with promising non-opioid treatments specifically targeting neuropathic pain. Neuropathic pain, characterized by nerve damage leading to burning, shooting, or tingling sensations, affects millions and often resists conventional therapies. The Center for Advanced Pain Studies (CAPS) at UT Dallas has made headlines with advancements that could redefine pain management, offering hope amid the opioid crisis.

This progress stems from innovative human tissue research and molecular discoveries, positioning UT Dallas as a hub for higher education-driven pain research in the United States.

The Scale of the Chronic Pain Epidemic in the United States

Chronic pain impacts approximately 24.3% of U.S. adults, equating to over 60 million people, with high-impact chronic pain—pain that significantly limits life or work activities—affecting 8.5%. Neuropathic pain, a subset involving damaged nerves, contributes to about 10% of cases, often linked to conditions like diabetes, shingles, or injury. The opioid crisis exacerbates this, with over 40 million acute pain patients prescribed opioids annually, many progressing to addiction.

Traditional treatments like opioids provide relief but carry risks of tolerance, dependence, and overdose. Non-opioid alternatives are urgently needed, and UT Dallas' work addresses this gap head-on.

Understanding Neuropathic Pain: Causes and Challenges

Nerve pain arises when the nervous system malfunctions, sending pain signals without injury. Common causes include diabetic neuropathy (affecting half of diabetes patients), chemotherapy-induced neuropathy, and post-herpetic neuralgia. Symptoms persist beyond three months, disrupting sleep, mood, and mobility.

Current options like gabapentinoids or antidepressants offer modest relief (30-50% reduction) with side effects like dizziness. The search for targeted, non-addictive therapies focuses on 'sleeping nociceptors'—silent sensory neurons that 'wake up' in chronic states, firing spontaneously.

UT Dallas' Center for Advanced Pain Studies: A Beacon of Innovation

Established at UT Dallas, CAPS integrates neuroscience, pharmacology, and clinical insights to tackle chronic pain and migraine. With over $10 million in NIH funding, the center pioneers non-opioid strategies, analyzing transcriptomics and proteomics from human and animal tissues. CAPS has spun out four companies, bridging academia to therapeutics.

Their multidisciplinary dashboards enable deep dives into pain biology, fostering discoveries like novel drug targets.

Dr. Theodore Price: Visionary Leader in Pain Neuroscience

Dr. Ted Price, Ashbel Smith Professor and CAPS director, has dedicated his career to non-opioid pain relief. A UT Dallas alumnus (BS '97), Price's lab elucidates molecular pain transitions, emphasizing human data over animal models. His quote captures the urgency: "We know from direct human physiological evidence that these cells are important in neuropathic pain." Recent NIH grants exceed $4 million for CRISPR-enabled screening.

Price's collaborative spirit drives international partnerships, accelerating from bench to bedside.

Unveiling Sleeping Nociceptors: The Cell Paper Breakthrough

In February 2026, Price and collaborators published in Cell the molecular architecture of human dermal sleeping nociceptors. Using Patch-seq on pig dorsal root ganglia (mimicking human), they identified oncostatin M receptor (OSMR) and somatostatin (SST) as markers. Oncostatin M injection selectively activated these neurons in humans, confirming specificity.Read the full study

This 'Rosetta stone' links electrical activity to genes, enabling targeted silencing for neuropathic relief. Dr. Angelika Lampert noted: "Now that we have all the information... we can really start to search for an entrance point to drive them back to normal."

Human Tissue Revolution and Phase 2 Drug Trials

CAPS' collaboration with Southwest Transplant Alliance provides human dorsal root ganglia, yielding 'next-level' insights. Funded by NIH HEAL Initiative, their non-opioid drug—targeting a human-derived mechanism—completed Phase 1 safety in late 2025 and entered Phase 2 efficacy trials for chronic pain in 2026. Price highlighted donor generosity: "The selfless gift... allows us to do research that we really didn't think was possible."

If successful, it could cure specific neuropathic pains, bypassing opioid pitfalls.KERA News coverage

Targeting Diabetic Neuropathy: $3.1 Million NIH Project

In tandem, a $3.1 million NIH grant funds exploration of methylglyoxal in diabetic neuropathy pain. Led by Dr. Muhammad Saad Yousuf with Price and others, it examines stress responses in human cells and knockout mice, aiming for non-opioid inhibitors.

• Step 1: Methylglyoxal elevates, inhibiting eIF2α.
• Step 2: Activates eIF2A, causing hyperexcitability.
• Step 3: Test inhibitors for pain relief over five years.

Funding, Collaborations, and Broader Impact

NIH HEAL Initiative accelerates these efforts, with PRECISION Network providing human data. International ties (Germany, Canada) enhance rigor. UT Dallas' role exemplifies higher education's pivot to translational research, potentially saving billions in healthcare costs.

Career Opportunities in Pain Research at UT Dallas

For aspiring researchers, CAPS offers PhD programs in neuroscience, postdoctoral roles, and faculty positions. Skills in transcriptomics, electrophysiology, and bioinformatics are prized. Explore openings via university job boards.

Photo by Vitaly Gariev on Unsplash

Future Outlook: A Post-Opioid Era?

UT Dallas' strides, alongside suzetrigine (FDA-approved 2025 NaV1.8 inhibitor), herald non-opioid dominance. Challenges remain: scaling human studies, trial success, access. Yet, with molecular targets identified, personalized pain therapies loom, improving lives for millions.

As Price envisions, silencing rogue neurons could end neuropathic suffering, underscoring universities' vital role.